This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
 
Luminex plans to launch a next-generation multiplex instrument next year that will be able to process more analytes and produce results twice as fast as its current Luminex 200 instrument, company officials said during the firm’s annual investors meeting in New York last week.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.